HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity

References

• Araldi RP, Sant’ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, Cerutti JM, de Souza EB. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–12. doi:10.1016/j.biopha.2018.06.149.
   PubMed Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. doi:10.1128/CMR.16.1.1-17.2003.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomavirus infections — a major cause of human cancers. Biochimica Et Biophysica Acta - Reviews On Cancer. 1996;1288:55–78. doi:10.1016/0304-419X(96)00020-0.
   PubMed Web of Science ®Google Scholar
• Stanley M. HPV - Immune response to infection and vaccination. Infect Agent Cancer. 2010;5(1). doi:10.1186/1750-9378-5-19.
   PubMedGoogle Scholar
• de Sanjose S, Delany-Moretlwe S. HPV vaccines can be the hallmark of cancer prevention. Lancet. 2019;394:450–1. doi:10.1016/s0140-6736(19)30549-5.
   PubMed Web of Science ®Google Scholar
• Pinto LA, Dillner J, Beddows S, Unger ER. Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018;36(32):4792–9. doi:10.1016/j.vaccine.2017.11.089.
   PubMed Web of Science ®Google Scholar
• Williamson A-L. Recent developments in human papillomavirus (HPV) vaccinology. Viruses. 2023;15:1440. doi:10.3390/v15071440.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, J KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51. doi:10.1056/NEJMoa020586.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. doi:10.1016/S0140-6736(06)68439-0.
   PubMed Web of Science ®Google Scholar
• Téblick L, Pattyn J, Van Keer S, De Smet A, De Coster I, Tjalma WAA, Rajbhandari I, Panicker G, Unger ER, Vorsters A, et al. Follow-up of humoral immune response after HPV vaccination using first-void urine: a longitudinal cohort study. J Med Virol. 2023;95(10). doi:10.1002/jmv.29133.
   PubMed Web of Science ®Google Scholar
• Pattyn J, Panicker G, Willhauck‐Fleckenstein M, Van Keer S, Téblick L, Pieters Z, Tjalma WAA, Matheeussen V, Van Damme P, Waterboer T, et al. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine. J Med Virol. 2020;92(12):3774–83. doi:10.1002/jmv.25841.
   PubMed Web of Science ®Google Scholar
• Van Keer S, Willhauck-Fleckenstein M, Pattyn J, Butt J, Tjalma WAA, Van Ostade X, Hens N, Van Damme P, Waterboer T, Vorsters A, et al. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. J Clin Virol. 2019;117:11–18. doi:10.1016/j.jcv.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Vorsters A, Van Damme P, Clifford G. Urine testing for HPV: rationale for using first void. BMJ. 2014;349:6252. doi:10.1136/bmj.g6252.
   PubMed Web of Science ®Google Scholar
• Pattyn J, Van Keer S, Téblick L, Van Damme P, Vorsters A. Non-invasive assessment of vaccine-induced HPV antibodies via first-void urine. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01657.
   PubMed Web of Science ®Google Scholar
• De Pauw H, Donders G, Weyers S, De Sutter P, Doyen J, Tjalma WAA, Vanden Broeck D, Peeters E, Van Keer S, Vorsters A, et al. Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Arch Public Heal. 2021;79. doi:10.1186/s13690-021-00667-4.
   PubMed Web of Science ®Google Scholar
• Cadman L, Reuter C, Jitlal M, Kleeman M, Austin J, Hollingworth T, Parberry AL, Ashdown-Barr L, Patel D, Nedjai B, et al. A randomized comparison of different vaginal self-sampling devices and urine for human papillomavirus testing—predictors 5.1. Cancer Epidemiol Biomarkers Prev. 2021;30:661–8. doi:10.1158/1055-9965.EPI-20-1226.
   PubMed Web of Science ®Google Scholar
• Kwak K, Yemelyanova A, Roden RBS. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2011;23(2):244–51. doi:10.1016/j.coi.2010.11.009.
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines – immune responses. Vaccine. 2012;30:F83–F7. doi:10.1016/j.vaccine.2012.04.106.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Castellsagué X, de Sanjosé S. Prophylactic human papillomavirus vaccines. Cancer Chemother Rev. 2008;3:23–34.
   Google Scholar
• Dykens JA, Peterson CE, Holt HK, Harper DM. Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally. Front Public Health. 2023;11. doi:10.3389/fpubh.2023.1067299.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Caruso G, Bogani G, Cavallari EN, Palaia G, Perniola G, Ralli M, Sorrenti S, Romeo U, Pernazza A, et al. HPV vaccination after primary treatment of HPV-Related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis. Nato Adv Sci Inst Se. 2022;10(2):239. doi:10.3390/vaccines10020239.
   Google Scholar
• Vorsters A, Van Damme P, Bosch FX. HPV vaccination: are we overlooking additional opportunities to control HPV infection and transmission? Int J Infect Dis. 2019;88:110–12. doi:10.1016/j.ijid.2019.09.006.
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YYS, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004;321:205–16. doi:10.1016/j.virol.2003.12.027.
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 y. Hum Vaccin. 2011;7(12):1343–58. doi:10.4161/hv.7.12.18281.
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix ™ and Gardasil ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5:705–19. doi:10.4161/hv.5.10.9518.
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA. Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol. 2008;15:60–4. doi:10.1128/CVI.00118-07.
   PubMedGoogle Scholar
• Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine. 2008;26(29–30):3608–16. doi:10.1016/j.vaccine.2008.04.074.
   PubMed Web of Science ®Google Scholar
• Téblick L, Lipovac M, Burdier FR, De Smet A, Bell M, van den Borst E, Matheeussen V, Vorsters A. Concentration strategies for spiked and naturally present biomarkers in non-invasively collected first-void urine. Eur J Med Res. 2024;29:131. doi:10.1186/s40001-024-01719-5.
   PubMed Web of Science ®Google Scholar
• Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One. 2013;8:75677. doi:10.1371/journal.pone.0075677.
   PubMed Web of Science ®Google Scholar
• Tsang SH, Basu P, Bender N, Herrero R, Kemp TJ, Kreimer AR, Müller M, Panicker G, Pawlita M, Pinto LA, et al. Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine. 2020;38(38):5997–6006. doi:10.1016/j.vaccine.2020.07.017.
   PubMed Web of Science ®Google Scholar
• Nie J, Huang W, Wu X, Wang Y. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J Med Virol. 2014;86(9):1542–55. doi:10.1002/jmv.23995.
   PubMed Web of Science ®Google Scholar
• Panicker G, Rajbhandari I, Pathak HN, Brady AM, Unger ER. Multiplex immunoassay to measure antibody response to nine HPV vaccine types. J Immunol Methods. 2021;498:113136. doi:10.1016/j.jim.2021.113136.
   PubMed Web of Science ®Google Scholar
• Li JZ, Guo Z, Sato T, Yuan B, Ma Y, Qian D, Zhong J, Jin M, Huang P, Che L, et al. Optimized application of the secreted nano-luciferase reporter system using an affinity purification strategy. PLoS One. 2018;13(5):1–15. doi:10.1371/journal.pone.0196617.
   Web of Science ®Google Scholar
• England CG, Ehlerding EB, Cai W. NanoLuc: a small luciferase is brightening up the field of bioluminescence. Bioconjug Chem. 2016;27(5):1175–87. doi:10.1021/acs.bioconjchem.6b00112.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang C, Feng S, Liu C, Li Y, Yang Y, Gao J, Li H, Meng S, Li L, et al. Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol. 2009;81(4):693–702. doi:10.1002/jmv.21435.
   PubMed Web of Science ®Google Scholar
• Nie J, Liu Y, Huang W, Wang Y. Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirus. Viruses. 2016;8(4):107. doi:10.3390/v8040107.
   PubMed Web of Science ®Google Scholar
• Day PM, Pang YYS, Kines RC, Thompson CD, Lowy DR, Schiller JT. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol. 2012;19:1075–82. doi:10.1128/CVI.00139-12.
   PubMed Web of Science ®Google Scholar
• Organization WH. Human papillomavirus laboratory manual human papillomavirus laboratory manual first edition, 2009. WHO Press Vol. 1; 2009.
   Google Scholar
• Buck CB, Pastrana DV, Lowy DR, Schiller J. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005;119:445–62.
   PubMedGoogle Scholar
• Buck CB, Thompson CD, Roberts JN, Müller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2:0671–80. doi:10.1371/journal.ppat.0020069.
   Web of Science ®Google Scholar
• Buck CB, Thompson CD. Production of papillomavirus‐based gene transfer vectors. Curr Protoc Cell Biol. 2007;37(1):26.1.1–26.1.19. doi:10.1002/0471143030.cb2601s37.
   Google Scholar
• Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. 1996;223:174–84. doi:10.1006/viro.1996.0466.
   PubMed Web of Science ®Google Scholar
• Molenberghs F, Verschuuren M, Barbier M, Bogers JJ, Cools N, Delputte P, Schelhaas M, De Vos WH. Cells infected with human papilloma pseudovirus display nuclear reorganization and heterogenous infection kinetics. Cytom Part A. 2022;101:1035–48. doi:10.1002/cyto.a.24663.
   PubMed Web of Science ®Google Scholar
• De Puysseleyr L, De Puysseleyr K, Vanrompay D, De Vos WH. Quantifying the growth of chlamydia suis in cell culture using high-content microscopy. Microsc Res Tech. 2017;80(4):350–6. doi:10.1002/jemt.22799.
   PubMed Web of Science ®Google Scholar
• De Vos WH, Van Neste L, Dieriks B, Joss GH, Van Oostveldt P. High content image cytometry in the context of subnuclear organization. Cytom Part A. 2010;77:64–75. doi:10.1002/cyto.a.20807.
   PubMed Web of Science ®Google Scholar
• Depuydt CE, Thys S, Beert J, Jonckheere J, Salembier G, Bogers JJ. Linear viral load increase of a single HPV-type in women with multiple HPV infections predicts progression to cervical cancer. Int J Cancer. 2016;139:2021–32. doi:10.1002/ijc.30238.
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Machin D, Walters SJ. Medical statistics: a textbook for health sciences. 2010.
   Google Scholar
• Unal I. Defining an optimal cut-point value in ROC analysis: an alternative approach. Comput Math Methods Med. 2017;2017:1–14. doi:10.1155/2017/3762651.
   Web of Science ®Google Scholar
• Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240–54. doi:10.1038/nrc.2018.13.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Clifford GM, Baussano I. Options for design of real-world impact studies of single-dose vaccine schedules. Vaccine. 2018;36(32):4816–22. doi:10.1016/j.vaccine.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Schiller JT. The potential benefits of HPV vaccination in previously infected women. 2016. doi:10.1016/j.ebiom.2016.06.042.
   Google Scholar
• Scherpenisse M, Schepp RM, Mollers M, Mooij SH, Meijer CJLM, Berbers GAM, van der Klis FRM. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol. 2013;20:1329–32. doi:10.1128/CVI.00153-13.
   PubMedGoogle Scholar
• Panicker G, Rajbhandari I, Gurbaxani BM, Querec TD, Unger ER. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types HHS public access. J Immunol Methods. 2015;417:107–14. doi:10.1016/j.jim.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Hagan AK, Zuchner T. Lanthanide-based time-resolved luminescence immunoassays. Anal Bioanal Chem. 2011;400(9):2847–64. doi:10.1007/s00216-011-5047-7.
   PubMed Web of Science ®Google Scholar
• Oh JE, Iijima N, Song E, Lu P, Klein J, Jiang R, Kleinstein SH, Iwasaki A. Migrant memory B cells secrete luminal antibody in the vagina. Nature. 2019;571:122–6. doi:10.1038/s41586-019-1285-1.
   PubMed Web of Science ®Google Scholar
• Prabhu PR, Carter JJ, Galloway DA. B CelL responses upon human papillomavirus (HPV) infection and vaccination. Nato Adv Sci Inst Se. 2022;10(6):837. doi:10.3390/vaccines10060837.
   Google Scholar
• Scherer EM, Smith RA, Gallego DF, Carter JJ, Wipf GC, Hoyos M, Stern M, Thurston T, Trinklein ND, Wald A, et al. A single human papillomavirus vaccine dose improves B cell memory in Previously infected subjects. EBioMedicine. 2016;10:55–64. doi:10.1016/j.ebiom.2016.06.042.
   PubMed Web of Science ®Google Scholar
• Gaudet RG, Breden F, Plummer F, Berry JD. Molecular characterization of the cervical and systemic B-cell repertoire. Mabs-austin. 2011;3(2):181–91. doi:10.4161/mabs.3.2.14858.
   PubMed Web of Science ®Google Scholar